Responses
Late-breaking abstracts
Clinical trials in-progress
808 Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)
Compose a Response to This Article
Other responses
No responses have been published for this article.
